Enterprise Products Partners L.P. Common Stock (EPD)

Total Costs & Expenses

$16.13B

Quarterly · Period ending: · USD

EPD logo

EPD Total Costs & Expenses

Latest reported$16.13B
EPD Quarterly Total Costs & Expenses ($0.00 → $16.13B)
High-resolution chart · PNG

EPD total costs & expenses history

Quarterly · USD. Dates are reporting period ends; fiscal years can differ from calendar years.

Enterprise Products Partners L.P. Common Stock Total Costs & Expenses — Quarterly (USD)
Period endingTotal Costs & Expenses (USD)
16,129,000,000
12,567,000,000
11,854,000,000
10,337,000,000
9,660,000,000
13,656,000,000
12,230,000,000
11,995,000,000
11,718,000,000
12,938,000,000
12,701,000,000
10,303,000,000
9,072,000,000
10,710,000,000
11,885,000,000
13,756,000,000
14,296,000,000
11,342,000,000
9,967,000,000
9,319,000,000
7,958,000,000
7,460,000,000
6,336,000,000
5,539,500,000
4,314,100,000
5,975,000,000
6,587,300,000
6,489,900,000
6,715,999,999
6,917,300,000
7,541,900,000
7,942,600,000
7,481,100,000
8,160,000,000
7,347,200,000
6,007,700,000
5,668,900,000
6,288,800,000
5,555,600,000
5,015,400,000
4,780,900,000
4,089,700,000
5,220,500,000
5,398,500,000
6,292,200,000
6,576,500,000
9,269,300,000
11,392,500,000
11,636,500,000
11,877,200,000
12,185,800,000
11,273,400,000
10,375,700,000
10,425,699,999
10,249,499,999
9,680,200,000
9,052,000,000
10,513,500,000
10,687,000,000
10,654,600,000
10,583,700,000
9,575,000,000
9,116,400,000
7,516,100,000
7,012,100,000
8,025,500,000
13,206,500,000
4,254,100,000
3,179,600,000
3,050,900,000
3,230,476,000
5,978,786,000
5,965,345,000
5,669,943,000
5,032,748,000
3,901,166,000
3,998,244,000
3,134,930,000
3,144,194,000
3,598,341,000
3,331,808,000
3,056,574,000
3,602,729,000
3,054,894,000
2,546,262,000
2,390,058,000
2,687,411,000
1,947,062,000
1,648,295,000
1,617,576,000
1,353,304,000
1,204,158,000
1,144,311,000
1,396,554,000
1,083,532,000
880,920,000
753,361,000
672,385,000
606,542,000
642,212,000
Data is provided for informational purposes only and does not constitute investment advice. Past performance is not indicative of future results.